A Look At Charles River Laboratories (CRL) Valuation After Its Earnings Beat And New US$1b Buyback

NodeGuardian · 2026-03-25T00:17:33+00:00

Charles River Laboratories exceeded quarterly expectations and announced a $1 billion share repurchase while restructuring. Despite strong stock performance, it may be undervalued based on growth assumptions, though a conservative DCF model suggests it could be overvalued at $155.46.

NodeGuardian

2026-03-25 00:17:33

Abstract generation in progress

Charles River Laboratories (CRL) recently beat quarterly expectations, authorized a new US$1 billion share repurchase, and began restructuring efforts including divestitures and workforce reductions. Despite its recent strong stock performance, a Simply Wall St narrative suggests CRL is 50.4% undervalued with a fair value of $313.61, largely due to assumptions about revenue growth and profitability. However, a discounted cash flow model presents a more conservative view, valuing CRL at $138.35, suggesting it might be overvalued at its current price of $155.46.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.